HANSOH PHARMAC. HD-00001 (3KY) — Cash Flow Reinvestment Rate
HANSOH PHARMAC. HD-00001 (3KY) has a Cash Flow Reinvestment Rate of 1.22x as of December 2025, reinvesting €8.20 Billion (capex €489.46 Million plus investments €-7.72 Billion) from operating cash flow of €6.74 Billion. For the full cash flow conversion analysis, see HANSOH PHARMAC. HD-00001 cash conversion from operations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
HANSOH PHARMAC. HD-00001 Cash Flow Reinvestment Rate (2021–2025)
Historical reinvestment intensity for HANSOH PHARMAC. HD-00001 across 5 annual periods. See HANSOH PHARMAC. HD-00001 leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Annual Cash Flow Reinvestment Rate for HANSOH PHARMAC. HD-00001 (2021–2025)
Year-by-year capital reinvestment analysis for HANSOH PHARMAC. HD-00001. See 3KY cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.22x | €8.20 Billion | €6.74 Billion | €489.46 Million | ▲ +115.4% |
| 2024 | 0.57x | €2.18 Billion | €3.86 Billion | €524.93 Million | ▲ +42.6% |
| 2023 | 0.40x | €1.24 Billion | €3.12 Billion | €362.52 Million | ▼ -81.3% |
| 2022 | 2.12x | €5.81 Billion | €2.74 Billion | €291.82 Million | ▲ +121.8% |
| 2021 | 0.96x | €2.46 Billion | €2.58 Billion | €475.44 Million | — |